Your session is about to expire
← Back to Search
Checkpoint Inhibitors for Cancer Recurrence After Stem Cell Transplant (CPIT001 Trial)
CPIT001 Trial Summary
This trial is testing a new cancer treatment that uses the body's own immune system to fight the disease.
CPIT001 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1289 Patients • NCT01285609CPIT001 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a current or suspected autoimmune disease.I have cancer that has spread to my brain or spinal cord.My lymphoma came back within a year after treatment and is now high-risk.I cannot or do not want to sign the consent form.I haven't taken high-dose steroids or immunosuppressants in the last 14 days.You had a bad reaction to nivolumab, ipilimumab, or any similar drugs before.I have received a stem cell transplant from a donor.I have an autoimmune disease treated with medication in the last 2 years.I haven't had cancer antibody treatment in the last 4 weeks or still have side effects.I have a history of or currently have non-infectious lung inflammation.I am using birth control to prevent pregnancy during and after the trial.I am a man and use highly effective birth control if having sex with a woman who can get pregnant.My transplant prep follows the specified guidelines.I can take care of myself but cannot do heavy physical work.My T cell lymphoma has not worsened after my last treatment.I have been diagnosed with HIV/AIDS.You have a positive test for Hepatitis B or Hepatitis C, showing that you have an ongoing infection.Women who could become pregnant must have a negative pregnancy test within 24 hours before starting nivolumab.I am using two birth control methods or am not having sex to join this study.My diffuse large B cell lymphoma did not fully respond to initial chemo but is stable or has specific genetic features.I have not received a live vaccine in the last 30 days.I am between 18 and 80 years old.I am currently receiving IV treatment for an infection.I have been treated with drugs that target the immune system.I have high-risk T cell lymphoma that hasn't worsened after initial treatment, and I don't have ALK-positive ALCL.I am eligible for a stem cell transplant at John Theurer Cancer Center.
- Group 1: All Participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the number of participants currently registered for this research project?
"Unfortunately, this medical study is presently not accepting applicants. It was first posted on June 7th 2016 and last updated on December 2nd 2022; however, there are 3304 lymphoma trials and 764 Ipilimumab studies which currently require participants."
Are there open opportunities for people to participate in this trial?
"The clinical study detailed on clinicaltrials.gov is not currently recruiting participants, despite its June 7th 2016 posting and December 2nd 2022 update. Nevertheless, there are 4068 other medical trials actively enrolling patients at the moment."
Have other studies been conducted to evaluate the effectiveness of Ipilimumab?
"Currently, there are 764 ongoing clinical trials for Ipilimumab with 87 of them in their final stages. The majority of these studies have been conducted out of Pittsburgh, Pennsylvania however they can be found at 44,216 other locations worldwide."
What indications typically warrant a prescription of Ipilimumab?
"Ipilimumab is a widely employed therapy for curbing the effects of anti-angiogenesis, and can also be used to combat an array of malignancies such as melanoma, squamous cell carcinoma, or other neoplastic growths."
Is this trial accessible to participants with advanced age?
"This clinical trial requires participants to be in the 18-80 age range. There are 505 studies suitable for minors and 3786 that cater specifically to seniors."
What criteria must potential participants meet in order to enroll in this experiment?
"This clinical trial is accepting 35 individuals aged between 18 and 80 who presently have lymphoma. Additionally, they must meet the following conditions: (GROUP D) patients having recurrent T cell lymphoma with at least stable disease after salvage therapy; Voluntary signed and dated IRB/IEC approved written informed consent form in accordance to regulatory and local regulations; Being of legal age on the signing date for their consent; (GROUP A) De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab plus anthracycline based multi-agent chemotherapy as well as remaining stationary after"
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger